Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Capecitabine Metronomic Chemotherapy Plus Endocrine Therapy for HR-positive, HER2-negative, Primary Breast Cancer: a Multicenter, Randomized, Double-blind Phase III Clinical Trial

NCT05063136 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT05063136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05063136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Capecitabine Metronomic Chemotherapy Plus Endocrine Therapy for HR-positive, HER2-negative, Primary Breast Cancer: a Multicenter, Randomized, Double-blind Phase III Clinical Trial
Lead sponsor
Henan Cancer Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
September 28, 2021
Completion date
September 30, 2028
Enrollment
1,979 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer